End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36.34 CNY | +0.25% | +4.58% | +26.97% |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.43 for the current year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.97% | 3.79B | C+ | ||
+20.94% | 72.16B | C+ | ||
-1.26% | 23.88B | C+ | ||
+8.25% | 8.35B | B | ||
+5.13% | 8.29B | C | ||
-19.42% | 8.18B | B- | ||
+5.56% | 4.81B | B- | ||
+16.83% | 4.4B | B+ | ||
-1.83% | 4B | B- | ||
-1.65% | 3.92B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600511 Stock
- Ratings China National Medicines Corporation Ltd.